The PROTEUS trial used ADT plus surgery as its control, not surgery alone. This design is controversial because many patients choose surgery specifically to avoid systemic therapies like ADT. This complicates the interpretation of results and reflects a disconnect from real-world patient motivations.

Shifting the view of prostate cancer from "androgen-driven" to "androgen receptor-driven" provides a new framework. In curative settings, after the androgen receptor is targeted for a defined period, restoring testosterone is seen as logical to improve patient quality of life once the cancer is destroyed.

A common mistake in testosterone replacement therapy is to suppress estrogen. For optimal libido, cardiovascular health, and bone density, men should aim to have estrogen levels as high as possible without side effects. High testosterone works best in concert with high estrogen.

There has been a significant population-level decline in male testosterone. The average level dropped from around 600 ng/dL in the late 1990s to 450 ng/dL by 2015. This is linked to modern lifestyle factors like rising obesity, endocrine-disrupting chemicals, and ultra-processed diets.

The term "hormone resistance" was misleading. Researchers discovered that even in a castrate state, prostate cancer tumors produce their own testosterone locally. This maintained androgen receptor signaling, proving the disease was still "androgen addicted" and opening the door for new targeted therapies.

In castration-resistant states, prostate cancer cells often amplify their androgen receptors (AR) to survive low testosterone levels. Bipolar androgen therapy exploits this by introducing a massive surge of testosterone. This "shocks" the over-amplified AR system, causing it to regress and disrupting downstream tumor growth pathways.

The term "APMR" (Androgen Pathway Modulator Resistant) is being adopted over "CRPC." This new terminology is more scientifically accurate for modern hormonal therapies and uses more patient-friendly language by removing the anxiety-inducing word "castration."

There is long-term data showing that adding hormone therapy to radiation can be curative for some prostate cancer patients. However, for surgery, historical and recent trials like PROTEUS have not demonstrated that perioperative hormone therapy adds a curative benefit, suggesting its role is more cytostatic in that context.

Counterintuitively, administering super-physiologic levels of testosterone can induce responses in certain castration-resistant prostate cancers. This strategy, called Bipolar Androgen Therapy, exploits the tumor's overexpressed receptors, turning a growth signal into a therapeutic vulnerability, though it remains a risky approach.